Cargando…

Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation

Postpartum atypical hemolytic uremic syndrome (aHUS) is a rare disorder associated with poor maternal and fetal outcomes. We describe a case of severe postpartum aHUS with recurrence in a kidney allograft after a second pregnancy. The patient had initially presented age 28 years with aHUS that devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garlo, Katherine, Dressel, Doug, Savic, Marizela, Vella, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438012/ https://www.ncbi.nlm.nih.gov/pubmed/29043127 http://dx.doi.org/10.5414/CNCS108491

Ejemplares similares

Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab
por: Andries, Gabriela, et al.
Publicado: (2017)

A Case of Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
por: Thajudeen, B., et al.
Publicado: (2013)

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome
por: Siedlecki, Andrew M., et al.
Publicado: (2018)

Atypical Hemolytic Uremic Syndrome After Liver Transplant Treated With Eculizumab
por: Bhatti, Sundus, et al.
Publicado: (2020)

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
por: Mauch, Teri J, et al.
Publicado: (2023)

Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in China
por: Sun, Ze-Jia, et al.
Publicado: (2016)

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report
por: Kourouklaris, Andreas, et al.
Publicado: (2014)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016)

Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)

Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)

Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
por: Gomes, Sara Madureira, et al.
Publicado: (2021)

The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
por: Santos, Mariana S, et al.
Publicado: (2022)

Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017)

Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
por: Azad, Farhan, et al.
Publicado: (2023)

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome
por: Jalbert, Arielle, et al.
Publicado: (2023)

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States
por: Wang, Yan, et al.
Publicado: (2023)

Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice
por: de Andrade, Luis Gustavo Modelli, et al.
Publicado: (2017)

Eculizumab as rescue therapy in a kidney transplant recipient with atypical hemolytic uremic syndrome: a case report
por: Oh, Young Ju, et al.
Publicado: (2022)

Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation
por: Singh, Priyamvada, et al.
Publicado: (2019)

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease
por: Hanna, Ramy M., et al.
Publicado: (2019)

Complement C3 mutation causing atypical hemolytic uremic syndrome successfully treated with eculizumab
por: Ellithi, Moataz, et al.
Publicado: (2021)

Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab
por: Webb, Tennille N., et al.
Publicado: (2015)

Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab
por: Raufi, Alexander G., et al.
Publicado: (2016)

Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2018)

189 Eculizumab Therapy for Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Publicado: (2021)

First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient
por: Jehn, Ulrich, et al.
Publicado: (2022)

The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report
por: Min, Eun-Ki, et al.
Publicado: (2023)

Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis
por: Gonzalez Suarez, Maria L., et al.
Publicado: (2019)

Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience
por: Kant, Sam, et al.
Publicado: (2020)

COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report
por: Cognard, Noëlle, et al.
Publicado: (2021)

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
por: Dorresteijn, Eiske M., et al.
Publicado: (2012)

Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome
por: Vilalta, Ramon, et al.
Publicado: (2012)

Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
por: Tsai, Han-Mou, et al.
Publicado: (2014)

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
por: Wijnsma, Kioa L., et al.
Publicado: (2019)

COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy
por: Gill, Jasmeet, et al.
Publicado: (2021)

The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center
por: Thomas, Katharine, et al.
Publicado: (2023)

Successful Discontinuation of Eculizumab in a Pediatric Patient With Atypical Hemolytic Uremic Syndrome and Underlying Systematic Lupus Erythematosus
por: Alhamoud, Issa, et al.
Publicado: (2022)

Importance of eculizumab treatment in recurrence of atypical hemolytic uremic syndrome during the SARS-CoV-2 pandemic
por: Tatar, Erhan, et al.
Publicado: (2021)

Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?
por: Kakajiwala, Aadil, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7bhb0rbethkkq1ff2nuafb9v7h